Human trials have begun on a potentially groundbreaking cancer drug

September 18, 2012 by Linda Mcsweeny

(Medical Xpress)—In medical science, remarkable things sometimes happen that make years of toiling in the lab worthwhile.

Most rewarding is a discovery that could save lives, or at least makes an illness easier to bear.

"The odds are very small but you have that chance," says Professor Philip Hogg, who is at the helm of the first human trials of a potential new therapy designed to shrink cancerous tumours.

Only a handful of Australian researchers get the chance to be involved in, yet alone lead, a human trial of a drug that could transform clinical practice.

Professor Hogg, who is director of the Lowy Research Centre and was the 2009 NSW Cancer Researcher of the Year, and his colleague Dr Pierre Dilda developed the compound that could provide an alternative to chemotherapy.

The compound, named PENAO, inhibits how tumours metabolise sugar and is the latest invention for the scientists, who began working together on new cancer drug strategies more than a decade ago.

PENAO works by making inactive a key protein in energy-producing structures in known as , Hogg says.

PENAO is a second-generation compound developed out of the success of trials in the UK of the first-generation compound, named GSAO.

Human trials of PENAO began in July at the Peter MacCallum Cancer Centre and at Royal Melbourne Hospital and will include patients with solid tumours, such as those of the breast, prostate, colon and brain.

"Tumours metabolise sugar differently than normal tissue," Hogg says. "The compounds we have made target this difference."

While there are hurdles to overcome, Hogg is hopeful the compounds will form the basis of new cancer therapies.

"The first-generation molecule we made – the GSAO – at best, would stop tumours from growing, so the hope for that compound was to turn cancer into a manageable disease.

"With this second-generation compound, we're hoping to be able to take the process a step further and actually shrink the tumours."

Hogg says the "early signs are good – PENAO is well tolerated like the first-generation drug and is much more effective in pre-clinical testing".

The trial involves about 20 patients and is expected to last 18 months.

Medical oncologist Dr Jayesh Desai is the principal investigator who oversaw treatment of the first patient, a woman with late-stage cervical cancer, at Royal Melbourne Hospital.

"We are very excited to have treated the first patient. PENAO offers a very positive step forward," he says.

The drug is pumped directly into the bloodstream, which is considered the best delivery pathway and easiest for the patient. Participants can take the pump home with them and need only weekly hospital visits for check-ups. The drug is delivered in two cycles over a total of 42 days.

Dilda says being able to take from the bench to the bedside has been "a great achievement".

"As research scientists, we are fortunate to be involved in projects that have an impact in 'real life'," he says.

Hogg admits he was excited when, about 12 years ago, he and his team discovered the compounds they made were knocking out the power supply of cancer cells.

But he adds there are "degrees of excitement", with many stages to complete before the discovery can translate into cancer treatments.

However it is the hope of delivering a breakthrough – similar to the story of the discovery of insulin that inspired him as a student – that keeps him going.

"You have the chance of doing something fantastic. We all understand it's very infrequent and the odds of us doing something really worthwhile are pretty small – very small – but there's that chance and often that's enough."

Explore further: Silencing a deadly conversation in breast cancer

Related Stories

Silencing a deadly conversation in breast cancer

June 2, 2011
While it is already known that breast cancer cells create the conditions for their own survival by communicating their needs to the healthy cells that surround them, Australian researchers have identified a new way of turning ...

Some breast cancer tumors may be resistant to a common chemotherapy treatment

March 27, 2012
Some breast cancer tumours may be resistant to a common chemotherapy treatment, suggests recent medical research at the University of Alberta.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.